TherapeuticsMD Inc (TXMD) Announces Positive Results From Its Phase 3 Rejoice Trial


TherapeuticsMD Inc (NYSEMKT:TXMD) shares are up big in after hours trading this afternoon after the company has announced positive top-line results from their Phase 3 Rejoice Trial for TX-004HR. The drug is used for the treatment of moderate to severe vaginal pain during sexual intercourse due to vaginal atrophy during menopause. The company likely will be submitting a New Drug Application to the FDA as soon as the first half of next year. Shares are currently trading up $2.92 or 44.72%.

“We are extremely encouraged that all three doses of TX-004HR studied in the Rejoice Trial demonstrated positive results,” said TherapeuticsMD CEO Robert G. Finizio. “With efficacy observed as early as two weeks and the convenience of the applicator-free vaginal softgel, we believe that, if approved, TX-004HR has the potential to offer a highly differentiated, new treatment option that meets the needs of the millions of postmenopausal women with VVA who are suffering from pain during sexual intercourse.”

The stock decreased 4.95% or $0.34 during the last trading session, hitting $6.53. About 1.41M shares traded hands or 48.16% up from the average. TXMD has risen 0.59% since May 4, 2015 and is uptrending. It has outperformed the S&P500 by 1.66%.

The institutional sentiment increased to 2.19 in Q2 2015. It’s up 0.01, from 2.18 in 2015Q1. The ratio improved, as 13 funds sold all their TherapeuticsMD Inc shares they owned while 23 reduced their positions. 34 funds bought stakes while 45 increased their total positions. Institutions now own 109.10 million shares which is 2.61% less than the previous share count of 112.02 million in 2015Q1.

Ra Capital Management Llc holds 1.33% of its total portfolio in TherapeuticsMD Inc, equating to 1.68 million shares. Ghost Tree Capital Llc owns 400,000 shares representing 1.09% of their total US portfolio. Moreover, Morgens Waterfall Vintiadis & Co Inc has 0.89% of their total portfolio invested in the company, equating to 180,000 shares. The New York-based Gilder Gagnon Howe & Co Llc has a total of 0.54% of their portfolio invested in the stock. Tekla Capital Management Llc, a Massachusetts-based fund reported 1.48 million shares owned.

TherapeuticsMD, Inc. is a women’s health care product company. The company has a market cap of $1.22 billion. The Firm is engaged in creating and commercializing products for women. It currently has negative earnings. The Firm is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products.